Total Payments
$228,127
2023 Payments
$105.04
Companies
27
Transactions
165
Medicare Patients
568
Medicare Billing
$66,186
Payment Breakdown by Category
Consulting$112,138 (49.2%)
Other$72,799 (31.9%)
Travel$22,747 (10.0%)
Research$17,181 (7.5%)
Food & Beverage$3,261 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,138 | 42 | 49.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,279 | 20 | 22.5% |
| Travel and Lodging | $22,747 | 32 | 10.0% |
| Honoraria | $21,520 | 5 | 9.4% |
| Unspecified | $17,181 | 13 | 7.5% |
| Food and Beverage | $3,261 | 53 | 1.4% |
Payments by Type
General
$210,945
152 transactions
Research
$17,181
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $44,613 | 33 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $29,664 | 30 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $21,347 | 8 | $0 (2017) |
| GENZYME CORPORATION | $20,566 | 13 | $0 (2020) |
| Amgen Inc. | $18,415 | 4 | $0 (2018) |
| Astellas Pharma Inc | $16,680 | 6 | $0 (2017) |
| Eli Lilly and Company | $16,344 | 18 | $0 (2022) |
| PFIZER INC. | $13,977 | 13 | $0 (2023) |
| CIPLA USA INC. | $10,000 | 1 | $0 (2018) |
| Genentech, Inc. | $7,091 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $105.04 | 1 | PFIZER INC. ($105.04) |
| 2022 | $20,076 | 10 | Bayer HealthCare Pharmaceuticals Inc. ($12,613) |
| 2021 | $21,864 | 16 | F. Hoffmann-La Roche AG ($9,127) |
| 2020 | $11,248 | 5 | GENZYME CORPORATION ($2,876) |
| 2019 | $20,870 | 27 | Eli Lilly and Company ($8,944) |
| 2018 | $61,132 | 34 | Amgen Inc. ($18,415) |
| 2017 | $92,832 | 72 | SANOFI-AVENTIS U.S. LLC ($21,347) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/06/2023 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $105.04 | General |
| Category: ONCOLOGY | ||||||
| 09/02/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 07/05/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 06/30/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $466.67 | Research |
| Study: IPATASERTIB PLUS ABIRATERONE VERSUS PLACEBO PLUS ABIRATERONE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ||||||
| 06/06/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,280.00 | General |
| 06/04/2022 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $130.94 | General |
| 04/19/2022 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 04/07/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $8,937.50 | General |
| Category: Oncology | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,616.13 | Research |
| Study: A PHASE 1B, OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN OR PROSTATE CANCER | ||||||
| 03/01/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 02/07/2022 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Oncology | ||||||
| 12/17/2021 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 09/15/2021 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| 07/16/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,098.29 | Research |
| Study: A PHASE 1B, OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN OR PROSTATE CANCER | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $2,005.53 | Research |
| Study: MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS • Category: BioOncology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $1,191.92 | Research |
| Study: MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS • Category: BioOncology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $1,146.92 | Research |
| Study: MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS • Category: BioOncology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $1,145.77 | Research |
| Study: MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS • Category: BioOncology | ||||||
| 06/03/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 04/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,280.00 | General |
| Category: Oncology | ||||||
| 04/12/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $328.16 | Research |
| Study: A PHASE 1B, OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN OR PROSTATE CANCER | ||||||
| 04/08/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $969.23 | Research |
| Study: TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE COMPARED WITH PLACEBO PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC PATIENTS PREVIOUSLY UNTREATED FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MCRPC. | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $904.54 | Research |
| Study: TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE COMPARED WITH PLACEBO PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC PATIENTS PREVIOUSLY UNTREATED FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MCRPC. | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $336.15 | Research |
| Study: MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS | F. Hoffmann-La Roche AG | $8,298 | 6 |
| A PHASE 1B, OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN OR PROSTATE CANCER | F. Hoffmann-La Roche AG | $3,043 | 3 |
| TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE COMPARED WITH PLACEBO PLUS ABIRATERONE PLUS PREDNISONE OR PREDNISOLONE IN ASYMPTOMATIC OR MILDLY SYMPTOMATIC PATIENTS PREVIOUSLY UNTREATED FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MCRPC. | F. Hoffmann-La Roche AG | $1,874 | 2 |
| IPATASERTIB PLUS ABIRATERONE VERSUS PLACEBO PLUS ABIRATERONE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | F. Hoffmann-La Roche AG | $466.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 132 | 218 | $70,629 | $13,299 |
| 2021 | 4 | 183 | 325 | $108,086 | $26,287 |
| 2020 | 7 | 253 | 377 | $100,236 | $26,600 |
Total Patients
568
Total Services
920
Medicare Billing
$66,186
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 82 | 127 | $34,320 | $6,901 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 50 | 91 | $36,309 | $6,398 | 17.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 102 | 228 | $77,132 | $18,496 | 24.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 50 | 65 | $17,295 | $4,890 | 28.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $8,799 | $1,729 | 19.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 20 | $4,860 | $1,171 | 24.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 61 | 109 | $29,651 | $7,123 | 24.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 65 | 89 | $21,137 | $6,226 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 67 | $23,249 | $6,108 | 26.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 57 | 65 | $9,652 | $2,768 | 28.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $7,314 | $1,943 | 26.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 18 | 18 | $6,336 | $1,704 | 26.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 15 | 16 | $2,897 | $727.89 | 25.1% |
About Dr. Christopher Sweeney, M.D
Dr. Christopher Sweeney, M.D is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659337038.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Sweeney, M.D has received a total of $228,127 in payments from pharmaceutical and medical device companies, with $105.04 received in 2023. These payments were reported across 165 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($112,138).
As a Medicare-enrolled provider, Sweeney has provided services to 568 Medicare beneficiaries, totaling 920 services with total Medicare billing of $66,186. Data is available for 3 years (2020–2022), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 04/25/2006
- Last Updated 02/02/2010
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1659337038
Products in Payments
- TAXOTERE (Drug) $21,067
- JEVTANA (Drug) $19,348
- TECENTRIQ (Biological) $18,980
- XGEVA (Biological) $18,415
- Xtandi (Drug) $16,680
- Xofigo (Drug) $14,355
- Perjeta (Biological) $13,693
- Nubeqa (Drug) $12,613
- ELIGARD (Drug) $6,775
- Erleada (Drug) $6,635
- Herceptin (Biological) $5,245
- XTANDI (Drug) $4,983
- CC-90011 (Drug) $3,710
- Non-Covered Product (Drug) $2,817
- TALZENNA (Drug) $2,625
- LUTATHERA (Drug) $2,000
- Non-Covered (Drug) $1,680
- NO PRODUCT DISCUSSED (Drug) $1,497
- OPDIVO (Biological) $1,280
- Abraxane (Drug) $600.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701